Javier Crespo is an expert in Hepatology at Marqués de Valdecilla University Hospital (Spain). As of October 2026, ScienceLeadR ranks Javier Crespo in the top 1% of experts worldwide for Alcohol-Induced Disorders, MASH and Hepatitis. Javier Crespo has authored 796 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 1 of them ongoing. SLR score: 3,381 (community average: 125). How the SLR is computed.

LeadR Profile

3 381 ScienceLeadR Reputation 3381
Network Map

Hepatology

Subspecialties: Gastroenterology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Director of the Research group in Marqués de Valdecilla Research Institute (IDIVAL-HUMV) and Head of the clinical group associated with CIBERehd (GVC16 / EHD / 4), a multidisciplinary and transversal group that includes biologists, biotechnologists, chemists, nurses, and physicians among its components.

Stable research lines in viral hepatitis (more than 25 years, I began with my doctoral thesis I read in 1993) and NASH (I started in 2001 with the publication of an original manuscript in Hepatology), I was a translational research study. I have experience in the management of multi-center projects. At this moment, our group is part of: the core of the Spanish Registry of Metabolic Associated Liver Disease (HEPAMET), the CIBERehd, the European consortium LITMUS for the study of NASH, we participate in more than 30 international clinical trials phase II and III. Moreover, we are running several research projects. I have broad experience in clinical and translational research. I have participated in more than 75 clinical trials phases I to III in HCV, and HBV. I have been granted with several R+D+I projects from public and private calls. I have given more than 100 presentations in national and international courses in liver diseases. I am an author in different guidelines and consensus in gastroenterology and hepatology. I have been a director and co-director in more than 20 national and international courses.


Organizations

Career arc: 1994 - 2026

Source: PubMed

Marqués de Valdecilla University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 796

Citations

Citations: 33 945 1st author: 91 Last author: 160 Unique author: 6


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.
PMID 42866838 — hepatitis d, therapeutics, hepatitis
Transl Gastroenterol Hepatol20260
Hepatitis C elimination protocol in Cantabria: Updated regional strategy and outcomes from a population-based cohort and opportunistic screening programs.
PMID 42775166 — hepatitis c, prevalence, antiviral agents, hepatitis
Sage Open Chronic Dis20260
Comment on Orozco-Beltrán et al. Evaluation, Management and Therapeutic Approach of Cardiovascular-Kidney-Metabolic Syndrome: A Multidisciplinary Delphi Expert Consensus. J. Clin. Med. 2025, 14, 8930.
PMID 42739643 — kidney, therapeutics, metabolic syndrome
J Clin Med20261
From millimeter to function and from procedure to program: the role of argon plasma coagulation in weight recovery after gastric bypass.
PMID 42714103 — digestive system diseases, recycling, drug therapy, argon plasma coagulation, gastric bypass, obesity, weight loss, therapeutics, plasma
Rev Esp Enferm Dig20260
Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology.
PMID 42653643 — carcinoma, hepatocellular, genetics, liver, clonal evolution, precision medicine, therapeutics, genetic risk score
Pharmaceuticals (Basel)20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Director: 2

By phase:

Phase 2 11
Phase 3 9
N/A 5
Phase 4 4
Phase 1 1

By status:

Completed 14
Unknown 9
Terminated 2
Withdrawn 2
Active not recruiting 1
Not yet recruiting 1
Recruiting 1

By type:

Interventional 27
Observational 3

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 3
multicentric5to9 1
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluate the Efficacy Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
NCT05622526 — liver diseases, safety, fecal microbiota transplantation, non-alcoholic fatty liver disease, liver, alcoholics, capsules, therapeutics, fatty liver, transplantation, fatty liver, alcoholic, microbiota
Phase 2Not yet recruiting2024

LeadR Networks

Main global connection map